ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 13,620,000 shares, a growth of 11.8% from the December 15th total of 12,180,000 shares. Based on an average daily trading volume, of 3,500,000 shares, the days-to-cover ratio is presently 3.9 days.

ADMA Biologics Stock Down 3.7 %

ADMA stock opened at $16.02 on Friday. The business has a 50 day moving average of $19.04 and a 200 day moving average of $17.25. The firm has a market cap of $3.79 billion, a PE ratio of 57.21 and a beta of 0.76. ADMA Biologics has a twelve month low of $4.86 and a twelve month high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period last year, the business earned $0.01 EPS. On average, research analysts forecast that ADMA Biologics will post 0.52 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares of the company's stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 3.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new position in shares of ADMA Biologics in the second quarter worth $29,000. Hollencrest Capital Management bought a new stake in ADMA Biologics in the 3rd quarter worth about $30,000. Larson Financial Group LLC purchased a new position in ADMA Biologics in the 3rd quarter worth about $31,000. GAMMA Investing LLC raised its position in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after buying an additional 967 shares during the last quarter. Finally, National Bank of Canada FI bought a new position in ADMA Biologics during the 3rd quarter valued at about $35,000. 75.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on ADMA shares. Raymond James upped their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Finally, HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.